drugset
drugset / Trial / NCT04193436

A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT

NCT04193436 ↗

Phase 1 Completed 23 enrolled Pfizer
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The study is proposed to characterize the effect of varying degrees of hepatic impairment on the plasma PK of PF-06835919

Timeline

Start
2020-01-21
Primary completion
2021-07-09
Completion
2021-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-06835919 Small molecule 25 mg Oral

Indications

No indication recorded.